• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Arvinas Appoints Kelly Page as Senior Vice President, Global Head of Oncology Strategy and Program Leadership

    4/3/23 7:00:16 AM ET
    $ARVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ARVN alert in real time by email

    NEW HAVEN, Conn., April 03, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kelly Page has joined the company as Senior Vice President, Global Head of Oncology Strategy and Program Leadership.

    "Kelly brings significant experience in the development of new oncology therapies from R&D through commercialization," said John Houston, Ph.D., Arvinas President and Chief Executive Officer. "We are pleased to welcome her to our Executive Committee and look forward to her valuable insight as we continue on our journey to become a late-stage development company."



    Ms. Page has over 25 years of global pharmaceutical industry experience from the research setting through global commercialization, with nearly 20 years of experience in oncology therapeutics. She recently served as Vice President, Head of Global Commercial, Hematology at AstraZeneca, where she was responsible for ensuring the successful commercialization of CALQUENCE®, with functional responsibility for commercial strategy and marketing across the hematology portfolio. Ms. Page has also held leadership positions of increasing responsibility at companies including Takeda Oncology and Pfizer.

    "I am proud to join such an exceptional company and the team that is leading the way in the development of targeted protein degradation therapeutics, with a strong mission to improve the lives of patients with serious diseases," said Ms. Page. "I look forward contributing my experience in the development and commercialization of oncology therapeutics and to support Arvinas' tremendous progress to date and exciting future ahead."

    About Arvinas

    Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has three investigational clinical-stage programs: bavdegalutamide and ARV-766 for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements regarding the potential advantages and therapeutic benefits of our product candidates, the future development and potential marketing approval and commercialization of our product candidates, including the initiation of and timing of data from our clinical trials. All statements, other than statements of historical facts, contained in this press release, including statements regarding our strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

    We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of various risks and uncertainties, including but not limited to:, whether we will be able to successfully conduct and complete clinical development of our product candidates, including whether we initiate and receive results from our clinical trials on our expected timelines or at all, obtain marketing approval for and commercialize our product candidates on our current timelines or at all and other important factors discussed in the "Risk Factors" sections contained in our quarterly and annual reports on file with the Securities and Exchange Commission. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we assume no obligation to update any forward-looking statements except as required by applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this release.

    Contacts

    Investors:

    Jeff Boyle

    347-247-5089

    [email protected]

    Media:

    Kirsten Owens

    203-584-0307

    [email protected]

     



    Primary Logo

    Get the next $ARVN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARVN

    DatePrice TargetRatingAnalyst
    6/2/2025$9.00Outperform → Market Perform
    Leerink Partners
    5/5/2025$11.00Buy → Hold
    Truist
    5/2/2025$10.00Buy → Hold
    Jefferies
    5/2/2025Buy → Hold
    TD Cowen
    3/13/2025$70.00 → $15.00Buy → Neutral
    Goldman
    3/12/2025$57.00 → $12.00Outperform → Neutral
    Wedbush
    3/11/2025Outperform → Perform
    Oppenheimer
    12/10/2024$69.00Buy
    BTIG Research
    More analyst ratings

    $ARVN
    SEC Filings

    See more
    • Arvinas Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

      8-K - ARVINAS, INC. (0001655759) (Filer)

      6/30/25 7:00:21 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Arvinas Inc.

      144 - ARVINAS, INC. (0001655759) (Subject)

      6/23/25 4:13:13 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - ARVINAS, INC. (0001655759) (Filer)

      6/13/25 7:12:58 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

      – ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In combination with small molecule inhibitors, ARV-393 demonstrated enhanced tumor growth inhibition, including tumor regressions, in models of aggressive diffuse large B-cell lymphoma (DLBCL) – NEW HAVEN, Conn., June 13, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today presented data from preclinical studies of ARV-393, the company's investigational PROteolysis TArge

      6/13/25 7:00:28 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer

      – This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE:PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human e

      6/6/25 7:00:03 AM ET
      $ARVN
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

      – Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (AITL) and transformed follicular lymphoma, and in combination with small molecule inhibitors in models of diffuse large B-cell lymphoma – NEW HAVEN, Conn., June 05, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical data for ARV-393 will be presented at the European Hematology Association (EHA) meeting, June 12-15, 2025 in Milan, Italy. ARV

      6/5/25 8:28:29 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Agarwal Sunil was granted 16,025 shares, increasing direct ownership by 113% to 30,166 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      6/30/25 6:14:09 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Smaldone Alsup Laurie was granted 16,025 shares, increasing direct ownership by 160% to 26,045 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      6/27/25 9:18:23 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Morrison Briggs was granted 16,025 shares, increasing direct ownership by 53% to 46,021 units (SEC Form 4)

      4 - ARVINAS, INC. (0001655759) (Issuer)

      6/27/25 9:14:34 PM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ARVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Arvinas downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Arvinas from Outperform to Market Perform and set a new price target of $9.00

      6/2/25 8:41:53 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Truist with a new price target

      Truist downgraded Arvinas from Buy to Hold and set a new price target of $11.00

      5/5/25 8:28:44 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Arvinas downgraded by Jefferies with a new price target

      Jefferies downgraded Arvinas from Buy to Hold and set a new price target of $10.00

      5/2/25 8:06:16 AM ET
      $ARVN
      Biotechnology: Pharmaceutical Preparations
      Health Care